Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Lefer
Lsu Health Sciences Center, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Exscien and NovoMedix
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. David Lefer is the principal investigator on the above referenced project sponsored by the NIH. The purpose of this project is to systematically decipher the role of endogenous hydrogen sulfide enzymes on the pathobiology of heart failure using a novel integrative approach. As required by CM-35, Dr. Lefer disclosed that he has equity in Exscien and NovoMedix. Exscien is a small biotech company that is currently developing a novel protein for the treatment of heart failure.
NovoMedix is a small biotech company that is developing novel drugs to treat heart failure.
Endogenous Hydrogen Sulfide Enzymes in Heart Failure
Project Narrative Heart failure (HF) is a leading cause of cardiovascular mortality and morbidity in the United States and patients with HF suffer from a poor quality of life and reduced lifespan. Hydrogen sulfide (H2S) is a powerful cardioprotective molecule with strong translational potential for the treatment of HF. We have proposed to systematically decipher the role of endogenous H2S enzymes on the pathobiology of HF using a novel integrative approach.
Filed on January 25, 2019.
Tell us what you know about David Lefer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Lefer”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Lefer | Lsu Health Sciences Center | Conflict of Interest | Sulfagenix, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.